- Home
- BHF vs AKRO Comparison
BHF vs AKRO Comparison
Compare BHF & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHF
- AKRO
- Stock Information
- Founded
- BHF 2016
- AKRO 2017
- Country
- BHF United States
- AKRO United States
- Employees
- BHF N/A
- AKRO N/A
- Industry
- BHF Life Insurance
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BHF Finance
- AKRO Health Care
- Exchange
- BHF Nasdaq
- AKRO Nasdaq
- Market Cap
- BHF 2.8B
- AKRO 2.8B
- IPO Year
- BHF N/A
- AKRO 2019
- Fundamental
- Price
- BHF $58.74
- AKRO $39.85
- Analyst Decision
- BHF Hold
- AKRO Strong Buy
- Analyst Count
- BHF 10
- AKRO 9
- Target Price
- BHF $58.20
- AKRO $76.29
- AVG Volume (30 Days)
- BHF 996.1K
- AKRO 1.1M
- Earning Date
- BHF 05-08-2025
- AKRO 05-16-2025
- Dividend Yield
- BHF N/A
- AKRO N/A
- EPS Growth
- BHF N/A
- AKRO N/A
- EPS
- BHF 8.71
- AKRO N/A
- Revenue
- BHF $8,611,000,000.00
- AKRO N/A
- Revenue This Year
- BHF $46.80
- AKRO N/A
- Revenue Next Year
- BHF $1.87
- AKRO N/A
- P/E Ratio
- BHF $6.64
- AKRO N/A
- Revenue Growth
- BHF 202.56
- AKRO N/A
- 52 Week Low
- BHF $40.00
- AKRO $17.86
- 52 Week High
- BHF $64.12
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- BHF 59.86
- AKRO 44.56
- Support Level
- BHF $57.00
- AKRO $41.60
- Resistance Level
- BHF $60.23
- AKRO $46.47
- Average True Range (ATR)
- BHF 2.45
- AKRO 2.26
- MACD
- BHF 0.60
- AKRO 0.08
- Stochastic Oscillator
- BHF 87.19
- AKRO 21.84
About BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.